The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)
Open accessAbstract
Background: Sodium-glucose cotransporter 2 inhibitors reduce the risk of heart failure hospitalization and cardiovascular death in patients with heart failure and reduced ejection fraction (HFrEF). However, their effects on cardiac structure and function in HFrEF are uncertain. Methods: We designed a multicenter, randomized, double-blind, placebo-controlled trial (the SUGAR-DM-HF trial [Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects in Patients With Diabetes Mellitus, or Prediabetes, and Heart Failure]) to investigate the cardiac effects of empagliflozin in patients in New York Heart Association functional class II to IV with a left ventricular (LV) ejection fraction ≤40% and type 2 diabetes or prediabetes. Patients were randomly assigned 1:1 to empagliflozin 10 mg once daily or placebo, stratified by age (<65 and ≥65 years) and glycemic status (diabetes or prediabetes). The coprimary outcomes were change from baseline to 36 weeks in LV end-systolic volume indexed to body surface area and LV global longitudinal strain both measured using cardiovascular magnetic resonance. Secondary efficacy outcomes included other cardiovascular magnetic resonance measures (LV end-diastolic volume index, LV ejection fraction), diuretic intensification, symptoms (Kansas City Cardiomyopathy Questionnaire Total Symptom Score, 6-minute walk distance, B-lines on lung ultrasound, and biomarkers (including N-terminal pro-B-type natriuretic peptide). Results: From April 2018 to August 2019, 105 patients were randomly assigned: mean age 68.7 (SD, 11.1) years, 77 (73.3%) male, 82 (78.1%) diabetes and 23 (21.9%) prediabetes, mean LV ejection fraction 32.5% (9.8%), and 81 (77.1%) New York Heart Association II and 24 (22.9%) New York Heart Association III. Patients received standard treatment for HFrEF. In comparison with placebo, empagliflozin reduced LV end-systolic volume index by 6.0 (95% CI, –10.8 to –1.2) mL/m 2 ( P =0.015). There was no difference in LV global longitudinal strain. Empagliflozin reduced LV end-diastolic volume index by 8.2 (95% CI, –13.7 to –2.6) mL/m 2 ( P =0.0042) and reduced N-terminal pro-B-type natriuretic peptide by 28% (2%–47%), P =0.038. There were no between-group differences in other cardiovascular magnetic resonance measures, diuretic intensification, Kansas City Cardiomyopathy Questionnaire Total Symptom Score, 6-minute walk distance, or B-lines. Conclusions: The sodium-glucose cotransporter 2 inhibitor empagliflozin reduced LV volumes in patients with HFrEF and type 2 diabetes or prediabetes. Favorable reverse LV remodeling may be a mechanism by which sodium-glucose cotransporter 2 inhibitors reduce heart failure hospitalization and mortality in HFrEF. Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT03485092.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationThe Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure
Cleland, J. G. F., Daubert, J.-C., Erdmann, E., Freemantle, N., Gras, D., Kappenberger, L., & Tavazzi, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050496 · Cited by 6,276
Cardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Self-citationCohn, J. N., Ferrari, R., & Sharpe, N. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00630-0 · Cited by 2,161
Green, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Cardiac T1 Mapping and Extracellular Volume (ECV) in clinical practice: a comprehensive review
Haaf, P., Garg, P., Messroghli, D. R., Broadbent, D. A., Greenwood, J. P., & Plein, S. (2016) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/s12968-016-0308-4 · Cited by 959
Maeda, K., Tsutamoto, T., Wada, A., Hisanaga, T., & Kinoshita, M. (1998) · American Heart Journal · doi:10.1016/s0002-8703(98)70041-9 · Cited by 791
Left Ventricular Remodeling in Heart Failure
Konstam, M. A., Kramer, D. G., Patel, A. R., Maron, M. S., & Udelson, J. E. (2011) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2010.10.008 · Cited by 765
Petersen, S. E., Aung, N., Sanghvi, M. M., Zemrak, F., Fung, K., Paiva, J. M., Francis, J. M., Khanji, M. Y., Lukaschuk, E., Lee, A. M., et al. (2016) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/s12968-017-0327-9 · Cited by 607
Verma, S., Mazer, C. D., Yan, A. T., Mason, T., Garg, V., Teoh, H., Zuo, F., Quan, A., Farkouh, M. E., Fitchett, D. H., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.042375 · Cited by 572
Kramer, D. G., Trikalinos, T. A., Kent, D. M., Antonopoulos, G. V., Konstam, M. A., & Udelson, J. E. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.05.011 · Cited by 492
Greenberg, B., Quinones, M. A., Koilpillai, C., Limacher, M., Shindler, D., Benedict, C., & Shelton, B. (1995) · Circulation · doi:10.1161/01.cir.91.10.2573 · Cited by 473
Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation: PRIME Study
Kang, D.-H., Park, S.-J., Shin, S.-H., Hong, G.-R., Lee, S., Kim, M.-S., Yun, S.-C., Song, J.-M., Park, S.-W., & Kim, J.-J. (2019) · Circulation · doi:10.1161/circulationaha.118.037077 · Cited by 340
Desai, A. S., Solomon, S. D., Shah, A. M., Claggett, B. L., Fang, J. C., Izzo, J., McCague, K., Abbas, C. A., Rocha, R., Mitchell, G. F., et al. (2019) · JAMA · doi:10.1001/jama.2019.12843 · Cited by 319
Reliability, validity, and responsiveness of the six-minute walk test in patients with heart failure
Demers, C., McKelvie, R. S., Negassa, A., & Yusuf, S. (2001) · American Heart Journal · doi:10.1067/mhj.2001.118468 · Cited by 312
Tardif, J.-C., O'Meara, E., Komajda, M., Böhm, M., Borer, J. S., Ford, I., Tavazzi, L., & Swedberg, K. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr311 · Cited by 300
Groenning, B. A., Nilsson, J. C., Sondergaard, L., Fritz-Hansen, T., Larsson, H. B. W., & Hildebrandt, P. R. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)01006-8 · Cited by 288
Wong, M., Staszewsky, L., Latini, R., Barlera, S., Volpi, A., Chiang, Y.-T., Benza, R. L., Gottlieb, S. O., Kleemann, T. D., Rosconi, F., et al. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02063-6 · Cited by 245
Lung Ultrasound in Acute Heart Failure
Platz, E., Campbell, R. T., Claggett, B., Lewis, E. F., Groarke, J. D., Docherty, K. F., Lee, M. M. Y., Merz, A. A., Silverman, M., Swamy, V., et al. (2019) · JACC: Heart Failure · doi:10.1016/j.jchf.2019.07.008 · Cited by 194
Self-citationSingh, J. S. S., Mordi, I. R., Vickneson, K., Fathi, A., Donnan, P. T., Mohan, M., Choy, A. M. J., Gandy, S., George, J., Khan, F., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2187 · Cited by 182
Colucci, W. S., Kolias, T. J., Adams, K. F., Armstrong, W. F., Ghali, J. K., Gottlieb, S. S., Greenberg, B., Klibaner, M. I., Kukin, M. L., & Sugg, J. E. (2007) · Circulation · doi:10.1161/circulationaha.106.666016 · Cited by 181
Packer, M. (2020) · Circulation: Heart Failure · doi:10.1161/circheartfailure.120.007197 · Cited by 176
Mewton, N., Opdahl, A., Choi, E., de Almeida, A. L. C., Kawel, N., Wu, C. O., Burke, G. L., Liu, S., Liu, K., Bluemke, D. A., et al. (2013) · Hypertension · doi:10.1161/hypertensionaha.111.198028 · Cited by 118
Neglecting Major Health Problems and Broadcasting Minor, Uncertain Issues in Lifestyle Science
Ioannidis, J. P. A. (2019) · JAMA · doi:10.1001/jama.2019.17576 · Cited by 115
Cardiovascular magnetic resonance reference ranges for the heart and aorta in Chinese at 3T
Le, T., Tan, R., Deyn, M. D., Goh, E., Han, Y., Leong, B. R., Cook, S. A., & Chin, C. W.-L. (2016) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/s12968-016-0236-3 · Cited by 108
Bellenger, N. G., Rajappan, K., Rahman, S. L., Lahiri, A., Raval, U., Webster, J., Murray, G. D., Coats, A. J. S., Cleland, J. G. F., & Pennell, D. J. (2004) · Heart · doi:10.1136/hrt.2003.015552 · Cited by 85
Liu, H., Wang, J., Pan, Y., Ge, Y., Guo, Z., & Zhao, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-60537-x · Cited by 39
Prognostic Importance of a New Measure of Global Systolic Heart Function in Healthy Adults
McComb, C., & Berry, C. (2013) · Hypertension · doi:10.1161/hypertensionaha.112.199992 · Cited by 3
Self-citation
Cited by
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Sattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599
Self-citationDiabetic vascular diseases: molecular mechanisms and therapeutic strategies
Li, Y., Liu, Y., Liu, S., Gao, M., Wang, W., Chen, K., Huang, L., & Liu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01400-z · Cited by 704
Frantz, S., Hundertmark, M. J., Schulz-Menger, J., Bengel, F. M., & Bauersachs, J. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac223 · Cited by 606
Metadata
- Authors
- Lee, M. M. Y., Brooksbank, K. J. M., Wetherall, K., Mangion, K., Roditi, G., Campbell, R. T., Berry, C., Chong, V., Coyle, L., Docherty, K. F., Dreisbach, J. G., Labinjoh, C., Lang, N. N., Lennie, V., McConnachie, A., Murphy, C. L., Petrie, C. J., Petrie, J. R., Speirits, I. A., Sourbron, S., Welsh, P., Woodward, R., Radjenovic, A., Mark, P. B., McMurray, J. J. V., Jhund, P. S., Petrie, M. C., & Sattar, N.
- Venue
- Circulation
- Published
- 2021-02-09
- Volume
- 143
- Issue
- 6
- Pages
- 516-525
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W3098234982
- Cited by
- 437
- References
- 28
- FWCI
- 34.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.